API | eplivanserin

eplivanserin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Eplivanserin was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis. ^Wikipedia

Chemistry

SMILES: CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F
InChIKey: VAIOZOCLKVMIMN-PRJWTAEASA-N
Mol. Mass: 328.39
ALogP: 3.53 Partition coefficient
ChEMBL Molecule:
eplivanserin

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, o-(2-(dimethylamino)ethyl)oxime, (z,e)-, (e)-2-butenedioate (2:1) (salt) | 4-((3z)-3-(2-dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate | eplivanserin | sr 46349 | sr-46349 | sr 46349b | sr-46349b

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Chronic Pain (Phase 2)

Fibromyalgia (Phase 2)

Sleep (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue